
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About
Pharming Group NV (PHAR)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: PHAR (1-star) has a low Upturn Star Rating. Not recommended to BUY.
1 Year Target Price $30.67
1 Year Target Price $30.67
2 | Strong Buy |
1 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -35.98% | Avg. Invested days 18 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 779.70M USD | Price to earnings Ratio - | 1Y Target Price 30.67 |
Price to earnings Ratio - | 1Y Target Price 30.67 | ||
Volume (30-day avg) 3 | Beta 0.54 | 52 Weeks Range 6.73 - 17.08 | Updated Date 08/15/2025 |
52 Weeks Range 6.73 - 17.08 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.14 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-07-31 | When - | Estimate -0.0125 | Actual 0.06 |
Profitability
Profit Margin -2.41% | Operating Margin (TTM) 3.27% |
Management Effectiveness
Return on Assets (TTM) 2.85% | Return on Equity (TTM) -3.7% |
Valuation
Trailing PE - | Forward PE 169.49 | Enterprise Value 780696045 | Price to Sales(TTM) 2.29 |
Enterprise Value 780696045 | Price to Sales(TTM) 2.29 | ||
Enterprise Value to Revenue 2.3 | Enterprise Value to EBITDA 26.45 | Shares Outstanding 68514800 | Shares Floating 670711932 |
Shares Outstanding 68514800 | Shares Floating 670711932 | ||
Percent Insiders - | Percent Institutions 0.09 |
Upturn AI SWOT
Pharming Group NV
Company Overview
History and Background
Pharming Group NV focuses on developing innovative protein replacement therapies and precision medicines for the treatment of rare diseases and immune disorders. It was founded in 1988.
Core Business Areas
- Recombinant Human C1 Inhibitor (rhC1INH): Development and commercialization of Ruconest, a recombinant human C1 inhibitor for the treatment of acute hereditary angioedema (HAE) attacks.
- Leniolimab: Development of Leniolimab, a fully human anti-CD40 monoclonal antibody, for the treatment of autoimmune diseases.
- Research and Development: Ongoing research and development activities focused on expanding its pipeline of innovative therapies for rare diseases.
Leadership and Structure
The leadership team consists of a CEO, CFO, CSO, and other key executives. The organizational structure includes departments for research and development, commercial operations, finance, and legal.
Top Products and Market Share
Key Offerings
- Ruconest: Ruconest (recombinant human C1 inhibitor) is Pharming's primary product, used to treat acute attacks of hereditary angioedema (HAE). Competitors include Takeda's Takhzyro and BioCryst's Orladeyo. Market Share is difficult to pinpoint but it is estimated to be less than 20%. Revenue is available in the companyu2019s financial statements.
- Leniolimab: Leniolimab is a fully human anti-CD40 monoclonal antibody in clinical development for various autoimmune indications. Currently it has no revenue.
Market Dynamics
Industry Overview
The rare disease market is characterized by high unmet medical needs, strong pricing power, and regulatory incentives for orphan drug development.
Positioning
Pharming Group NV is positioned as a specialized biopharmaceutical company focused on developing and commercializing innovative therapies for rare diseases, with Ruconest as its primary revenue driver.
Total Addressable Market (TAM)
The TAM for HAE and related conditions is estimated to be in the billions of dollars globally. Pharming aims to capture a significant share of this market through continued commercialization of Ruconest and development of new therapies.
Upturn SWOT Analysis
Strengths
- Established product (Ruconest) with demonstrated efficacy
- Specialized focus on rare diseases
- Proprietary technology platform
- Strong intellectual property protection
Weaknesses
- Reliance on a single primary product (Ruconest)
- Limited commercial infrastructure compared to larger pharmaceutical companies
- Risk of competition from new therapies
- Regulatory hurdles
Opportunities
- Expansion of Ruconest into new markets
- Development of new therapies for rare diseases
- Strategic collaborations and acquisitions
- Favorable regulatory environment for orphan drugs
Threats
- Competition from biosimilars or generics
- Pricing pressures from payers
- Clinical trial failures
- Adverse regulatory decisions
Competitors and Market Share
Key Competitors
- TAK
- BCRX
Competitive Landscape
Pharming Group NV faces competition from larger pharmaceutical companies with more extensive resources and established market positions. Pharming's competitive advantage lies in its specialized focus on rare diseases and its proprietary technology platform.
Growth Trajectory and Initiatives
Historical Growth: Historical growth would be evaluated based on past revenue growth, profitability, and other key performance indicators. This data is subject to change.
Future Projections: Future growth projections would be based on analyst estimates and company guidance, taking into account factors such as market trends, competition, and regulatory developments. This data is subject to change.
Recent Initiatives: Recent initiatives could include new product launches, strategic partnerships, or acquisitions. This data is subject to change.
Summary
Pharming Group NV is a specialized biopharmaceutical company focused on rare diseases. Ruconest drives current revenue, while Leniolimab offers future potential. Pharming faces competition from larger companies but benefits from a focused strategy and proprietary technology. They need to diversify revenue and look out for new competitive drugs being developed.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
The data provided is for informational purposes only and should not be considered financial advice. Market data is subject to change and accuracy cannot be guaranteed.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Pharming Group NV
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-12-23 | CEO & Executive Director Mr. Fabrice Chouraqui Ph.D., Pharm.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 404 | Website https://www.pharming.com |
Full time employees 404 | Website https://www.pharming.com |
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. It has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.